MCID: ADN027
MIFTS: 60

Adenomyosis

Categories: Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adenomyosis

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 57 11 19 75 43 14 16 33
Endometriosis of Uterus 11 14 71 31
Endometriosis of Myometrium 11 33
Endometriosis, Myometrium 11 33
Endometriosis Interna 11 33
Internal Endometriosis 33
Uterine Adenomyosis 11
Adenomyosis Uteri 33

Characteristics:


Inheritance:

Autosomal vs X-linked dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:288
OMIM® 57 600458
ICD9CM 34 617.0
MeSH 43 D062788
NCIt 49 C6996
SNOMED-CT 68 76376003
ICD10 31 N80.0
MedGen 40 C0341858
ICD11 33 171294592
UMLS 71 C0341858

Summaries for Adenomyosis

GARD: 19 Adenomyosis is a condition that affects the uterus. In women with Adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown.

MalaCards based summary: Adenomyosis, also known as endometriosis of uterus, is related to leiomyoma and adenomyoma. An important gene associated with Adenomyosis is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Oxytocin and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and neutrophil, and related phenotypes are abnormal bleeding and dysmenorrhea

OMIM®: 57 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458) (Updated 08-Dec-2022)

Disease Ontology: 11 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

Wikipedia: 75 Adenomyosis is a medical condition characterized by the growth of cells that proliferate on the inside... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 446)
# Related Disease Score Top Affiliating Genes
1 leiomyoma 31.2 TP53 OXTR ESR1 CYP19A1 BCL2
2 adenomyoma 31.2 HOXA10 ESR1 CTNNB1
3 ovarian cyst 30.9 MUC16 ESR1 CYP19A1
4 myoma 30.9 TP53 HOXA10 ESR1 CYP19A1 BCL2
5 endometrial adenocarcinoma 30.7 TP53 PTEN ESR1
6 endometriosis of ovary 30.6 PTEN ESR1 CYP19A1
7 infertility 30.5 MMP9 MMP2 ITGB3 IGFBP1 HOXA10 ESR1
8 preterm premature rupture of the membranes 30.5 MMP9 MMP2 IGFBP1
9 vaginal discharge 30.5 IGFBP1 ESR1 CYP19A1
10 endometrial stromal sarcoma 30.4 TP53 ESR1 CYP19A1
11 endometriosis 30.4 VEGFA TP53 PTGS2 PTEN MUC16 MMP2
12 leiomyosarcoma 30.3 VEGFA TP53 MUC16 ESR1 BCL2
13 fibroma 30.2 MUC16 ESR1 CTNNB1
14 estrogen excess 30.1 PTEN GPER1 ESR1 CYP19A1
15 suppressor of tumorigenicity 3 30.1 TP53 BCL2
16 cerebral artery occlusion 30.1 VEGFA MMP9 BCL2
17 smooth muscle tumor 30.1 MMP2 ESR1 BCL2
18 adenocarcinoma 30.1 VEGFA TP53 PTGS2 PTEN MMP9 MMP2
19 fallopian tube carcinoma 30.0 VEGFA TP53 PTEN
20 adhesions of uterus 30.0 VEGFA HOXA10 ESR1
21 uterine sarcoma 30.0 ESR1 CYP19A1
22 endosalpingiosis 30.0 TP53 ESR1
23 endometrial disease 30.0 PTGS2 IGFBP1 HOXA10 ESR1
24 cystitis 30.0 VEGFA TP53 PTGS2 NGF
25 aromatase excess syndrome 29.9 GPER1 ESR1 CYP19A1
26 bizarre leiomyoma 29.9 TP53 ESR1
27 serous cystadenocarcinoma 29.9 TP53 PTEN MUC16 MMP2 ESR1 CTNNB1
28 varicose veins 29.9 VEGFA MMP9 MMP2 ESR1 BCL2
29 pelvic organ prolapse 29.9 PTGS2 MMP9 ESR1 CTNNB1
30 endometrial hyperplasia 29.9 VEGFA TP53 PTEN HOXA10 ESR1 CYP19A1
31 endometrioid ovary carcinoma 29.9 TP53 PTEN CTNNB1
32 insulin-like growth factor i 29.8 VEGFA ITGB3 IGFBP1 ESR1
33 chronic cystitis 29.8 TP53 PTGS2 NGF
34 uterine corpus cancer 29.8 TP53 PTEN MUC16 ESR1 CTNNB1
35 gallbladder disease 29.8 VEGFA TP53 CTNNB1 BCL2
36 uterine carcinosarcoma 29.7 TP53 PTGS2 PTEN ESR1 CTNNB1
37 ureteral obstruction 29.7 TP53 PTGS2 CTNNB1
38 carcinosarcoma 29.7 TP53 PTEN CTNNB1
39 cervical squamous cell carcinoma 29.6 VEGFA TP53 PTEN MMP2
40 female reproductive endometrioid cancer 29.5 TP53 PTEN ESR1 CTNNB1
41 papilloma 29.4 VEGFA TP53 PTGS2 PTEN BCL2
42 liposarcoma 29.4 VEGFA TP53 PTEN CTNNB1 BCL2
43 thrombocytopenia 29.3 VEGFA MMP9 MMP2 ITGB3 HOXA10 CYP19A1
44 wilms tumor 1 29.3 VEGFA TP53 PTEN ESR1 CTNNB1 BCL2
45 endometrial cancer 29.2 VEGFA TP53 PTGS2 PTEN MUC16 MMP9
46 cervical cancer 29.2 TP53 PTGS2 PTEN MMP2 CTNNB1 BCL2
47 ovarian cancer 28.5 VEGFA TP53 SPP1 PTGS2 PTEN MUC16
48 uterine anomalies 11.1
49 fallopian tube endometriosis 11.0
50 leiomyoma, uterine 10.7

Comorbidity relations with Adenomyosis via Phenotypic Disease Network (PDN):


Asherman's Syndrome Cervix Uteri Carcinoma in Situ
Chronic Salpingo-Oophoritis Endometriosis of Ovary
Fallopian Tube Endometriosis Female Stress Incontinence
Myofibroma Submucous Uterine Fibroid
Subserous Uterine Fibroid

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

Human phenotypes related to Adenomyosis:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal bleeding 30 HP:0001892
2 dysmenorrhea 30 HP:0100607
3 adenomyosis 30 HP:0034326

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM®:

600458 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Adenomyosis:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 ANXA2 BCL2 CTNNB1 CYP19A1 ESR1 GPER1
2 homeostasis/metabolism MP:0005376 10.48 ANXA2 BCL2 CTNNB1 CYP19A1 ESR1 GPER1
3 nervous system MP:0003631 10.47 BCL2 CTNNB1 CYP19A1 ESR1 HOXA10 ITGB3
4 muscle MP:0005369 10.42 BCL2 CTNNB1 CYP19A1 ESR1 ITGB3 MMP2
5 renal/urinary system MP:0005367 10.36 BCL2 CTNNB1 CYP19A1 ESR1 ITGB3 MMP2
6 cardiovascular system MP:0005385 10.36 ANXA2 BCL2 CTNNB1 CYP19A1 ESR1 GPER1
7 neoplasm MP:0002006 10.35 BCL2 CTNNB1 ESR1 ITGB3 MMP2 MMP9
8 normal MP:0002873 10.35 CTNNB1 CYP19A1 ESR1 ITGB3 MMP2 NGF
9 endocrine/exocrine gland MP:0005379 10.34 BCL2 CTNNB1 CYP19A1 ESR1 GPER1 HOXA10
10 cellular MP:0005384 10.32 BCL2 CTNNB1 CYP19A1 ESR1 HOXA10 IGFBP1
11 liver/biliary system MP:0005370 10.31 CTNNB1 CYP19A1 ESR1 GPER1 IGFBP1 ITGB3
12 digestive/alimentary MP:0005381 10.27 BCL2 CTNNB1 CYP19A1 ESR1 HOXA10 ITGB3
13 behavior/neurological MP:0005386 10.25 BCL2 CTNNB1 CYP19A1 ESR1 MMP2 MMP9
14 immune system MP:0005387 10.25 BCL2 CTNNB1 CYP19A1 ESR1 GPER1 IGFBP1
15 reproductive system MP:0005389 10.25 BCL2 CTNNB1 CYP19A1 ESR1 GPER1 HOXA10
16 no phenotypic analysis MP:0003012 10.2 CTNNB1 ESR1 GPER1 NGF OXTR PTGS2
17 limbs/digits/tail MP:0005371 10.16 CTNNB1 ESR1 GPER1 HOXA10 MMP9 PTEN
18 embryo MP:0005380 10.16 BCL2 CTNNB1 ESR1 ITGB3 NDUFA13 PTEN
19 respiratory system MP:0005388 10.07 CTNNB1 ESR1 ITGB3 MMP2 MMP9 PTEN
20 skeleton MP:0005390 10.07 CTNNB1 CYP19A1 ESR1 GPER1 HOXA10 ITGB3
21 vision/eye MP:0005391 9.93 BCL2 CTNNB1 CYP19A1 ITGB3 MMP2 MMP9
22 hematopoietic system MP:0005397 9.8 ANXA2 BCL2 CTNNB1 CYP19A1 ESR1 GPER1
23 integument MP:0010771 9.44 BCL2 CTNNB1 CYP19A1 ESR1 ITGB3 MMP2

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181
6
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
7
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
8
Buserelin Approved, Investigational Phase 4 57982-77-1 42615 50225
9 Analgesics Phase 4
10 Antirheumatic Agents Phase 4
11 Antipyretics Phase 4
12 Cyclooxygenase Inhibitors Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Estrogen Receptor Antagonists Phase 4
17 Estrogen Antagonists Phase 4
18 Aromatase Inhibitors Phase 4
19
Ethanol Approved Phase 2, Phase 3 64-17-5 702
20
Lactitol Approved, Investigational Phase 2, Phase 3 585-86-4 157355
21
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
22
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
23
Ramosetron Investigational Phase 3 132036-88-5 4442 108000
24 Neurotransmitter Agents Phase 3
25 Antiemetics Phase 3
26 Gastrointestinal Agents Phase 3
27 Antineoplastic Agents, Hormonal Phase 2, Phase 3
28 Trace Elements Phase 3
29 Micronutrients Phase 3
30
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
31
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
32
Quinagolide Approved, Investigational Phase 2 87056-78-8
33 Dopamine agonists Phase 2
34 Dopamine Agents Phase 2
35
Bromocriptine Approved, Investigational, Withdrawn Phase 1 25614-03-3 31101
36 Antiparkinson Agents Phase 1
37
Drospirenone Approved Early Phase 1 67392-87-4 68873
38
Acetylsalicylic acid Approved, Vet_approved Early Phase 1 50-78-2 2244
39
Racepinephrine Approved, Vet_approved 51-43-4, 329-65-7 838 5816
40
Butorphanol Approved, Illicit, Vet_approved 58786-99-5, 42408-82-2 5361092
41
Sodium citrate Approved, Investigational 68-04-2 23431961
42
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
43
Oxycodone Approved, Illicit, Investigational 76-42-6 5284603
44
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3 3680
45
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 3003 5743
46
Dienogest Approved 65928-58-7 13175121 68861
47
Norethisterone Approved 68-22-4 199472 6230
48
Iodine Approved, Investigational Early Phase 1 7553-56-2 807
49
Bupivacaine Approved, Investigational Early Phase 1 2180-92-9, 38396-39-3 2474
50
Triamcinolone Approved, Vet_approved Early Phase 1 124-94-7 31307

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Unknown status NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
2 Use of Oxytocin in MRI-HIFU Treatment Unknown status NCT03937401 Phase 4 Oxytocin
3 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
4 A Controlled Trial on Adenomyosis Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus GnRH Analog Alone Recruiting NCT03421639 Phase 4 GnRH analog (3,75mg Leuprolide);Aromatase inhibitor plus GnRH analog (3,75mg Leuprolide)
5 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Recruiting NCT03946722 Phase 4 GnRH analogue downregulation
6 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
7 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
8 Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous/Transvaginal Microwave Ablation, Evaluated by Validated Questionnaires Unknown status NCT04209127 Phase 2, Phase 3
9 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
10 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
11 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Completed NCT02437175 Phase 3
12 Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre,Randomized Clinical Trial Completed NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
13 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
14 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
15 Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study Recruiting NCT04356664 Phase 2, Phase 3 GnRH agonist
16 Phase III Trial to Assess Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI Outcomes in Infertile Women Presenting With Adenomyosis. Withdrawn NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
17 A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis Completed NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
18 Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial Completed NCT01601366 Phase 2 Combined oral contraceptives
19 Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis Completed NCT02587000 Phase 2 Ulipristal acetate;Placebo
20 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
21 Vaginal Bromocriptine for the Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
22 Prospective Validation of a Prediction Model for Diagnosing Adenomyosis With Ultrasound. Unknown status NCT04135118
23 Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Adenomyosis Unknown status NCT02954757
24 A Multi-omics Study on the Tumorigenesis of Adenomyosis Unknown status NCT03742843
25 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
26 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
27 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
28 A Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis Unknown status NCT04010487
29 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
30 A Study of Cooperative Network of Diagnosis and Treatment of Uterine Adenomyosis. Unknown status NCT03230994
31 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study Unknown status NCT01259180
32 Clinical Randomized Controlled Trial of Aspirin in the Treatment of Pregnant Women With Adenomyosis on Reducing Preterm Delivery Unknown status NCT04535804 Early Phase 1 Aspirin/placebo
33 The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer Unknown status NCT02086344
34 A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Paracervical Block Before Total Laparoscopic Hysterectomy for Postoperative Pain Control (PALAPA): Unknown status NCT03792009 5% bupivacaine;Normal saline
35 Role of Abdominal Drainage for Laparoscopic Cholecystectomy a Prospective Randomised Study Unknown status NCT03909360
36 Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function in Patients Undergoing Laparoscopic Hysterectomy: a Double-blind, a Randomized Controlled Trial Unknown status NCT04295109 the drug of intravenous patient-controlled analgesia
37 Health-Related Quality of Life Among Women Receiving Hysterectomy in National Taiwan University Hospital Unknown status NCT00155870
38 Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
39 Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit? Completed NCT03104309
40 Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
41 Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
42 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
43 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
44 Value of Transvaginal Ultrasound, Transvaginal Sonographic Elastography and MRI for the Diagnosis of Adenomyosis Completed NCT04665414
45 Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Completed NCT04830085
46 The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis Completed NCT02340533
47 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I Completed NCT02201719
48 The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis Completed NCT05419414
49 Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri Completed NCT03890042 Dienogest group;Gestodene-Ethinyl Estradiol
50 The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization Completed NCT02056717 Dexamethasone;Normal saline

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

Organs/tissues related to Adenomyosis:

MalaCards : Uterus, Ovary, Neutrophil, Smooth Muscle, Brain, Endothelial, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 3377)
# Title Authors PMID Year
1
Adenomyosis: evidence for genetic cause. 62 57
7762596 1995
2
The elusive adenomyosis of the uterus. Its historical past and its present state of recognition. 62 57
13890115 1962
3
Real-world outcomes of the levonorgestrel-releasing intrauterine system for heavy menstrual bleeding or dysmenorrhea in Japanese patients: A prospective observational study (J-MIRAI). 62
36057322 2022
4
Intrapartum uterine rupture following ultrasound-guided high-intensity focused ultrasound ablation of uterine fibroid and adenomyosis. 62
35748875 2022
5
Adenomyosis decreases the live birth rate but may not affect perinatal outcomes in assisted reproductive cycles. 62
35521659 2022
6
Transvaginal ultrasound versus magnetic resonance imaging for diagnosing adenomyosis: A systematic review and head-to-head meta-analysis. 62
36461921 2022
7
Immunometabolic profiling of cervicovaginal lavages identifies key signatures associated with adenomyosis. 62
36419846 2022
8
Role of inflammatory factors in the etiology and treatment of recurrent implantation failure. 62
36162310 2022
9
Strategies for modelling endometrial diseases. 62
36050476 2022
10
Secondary alloanti-D immunization post transfusion of "Asia type" DEL red blood cells. 62
35623958 2022
11
Population attributable fraction of risk factors for low birth weight in the Japan Environment and Children's Study. 62
36240622 2022
12
Endometrial hyperplasia and pyometra in captive lions (Panthera leo) and tigers (Panthera tigris). 62
35787088 2022
13
Association between Endometriosis and Risk of Preeclampsia in Women Who Conceived Spontaneously: A Systematic Review and Meta Analysis. 62
36403695 2022
14
Expert opinion on the use of transvaginal sonography for presurgical staging and classification of endometriosis. 62
36367580 2022
15
Laparoscopic Adenomyomectomy under Real-Time Intraoperative Ultrasound Elastography Guidance: A Case Series and Feasibility Study. 62
36431184 2022
16
High-intensity focused ultrasound ablation combined with systemic methotrexate treatment of intramural ectopic pregnancy: A case report. 62
36401379 2022
17
An innovative surgical approach: suture fixation of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis. 62
36384588 2022
18
Altered Expression of Interleukin-18 System mRNA at the Level of Endometrial Myometrial Interface in Women with Adenomyosis. 62
36354688 2022
19
Claudin-10 Expression Is Increased in Endometriosis and Adenomyosis and Mislocalized in Ectopic Endometriosis. 62
36428908 2022
20
Managing the triad of triple mullerian anomaly, endometriosis and adenomyosis - A case report. 62
36302313 2022
21
The Effect of Uterine Adenomyosis on IVF Outcomes: a Systematic Review and Meta-analysis. 62
34981458 2022
22
Postpartum degeneration of adenomyosis with diffuse cyst-like changes and localized hemorrhage detected by sequential magnetic resonance imaging. 62
35915563 2022
23
[Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis]. 62
36456483 2022
24
A stepwise approach to robotic diffuse adenomyosis resection with double flap and concomitant abdominal cerclage. 62
36171150 2022
25
Comparison of recurrence rate and risk factors in patients with focal adenomyosis with and without medical treatment after conservative surgery. 62
36334061 2022
26
An update on uterine artery embolization for uterine leiomyomata and adenomyosis of the uterus. 62
36222200 2022
27
Multidisciplinary view on uterine junctional zone in uteri affected by adenomyosis: explaining discrepancies between MRI and transvaginal ultrasound images on a microscopic level. 62
36370446 2022
28
Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target. 62
36362323 2022
29
Bioengineering trends in female reproduction: a systematic review. 62
35652272 2022
30
Distinct clinicopathological features of ovarian endometriosis after long-term exposure to mifepristone. 62
36348508 2022
31
Life-threatening anemia due to uterine fibroids: A case series. 62
36237601 2022
32
Efficacy of Transabdominal Ultrasound-guided Percutaneous Microwave Ablation in the Treatment of Symptomatic Adenomyosis: A Retrospective Cohort Study. 62
36384213 2022
33
Acute late presentation of a functioning non-communicating rudimentary uterine horn containing an adenomyosis: A case report. 62
36132060 2022
34
Prediction of risk factors for first trimester pregnancy loss in frozen-thawed good-quality embryo transfer cycles using machine learning algorithms. 62
36399255 2022
35
Pelvic pain and venous congestion revisited: prospective study examining relationship between chronic pelvic pain and uterine venous size and blood flow. 62
36436120 2022
36
Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology. 62
36099328 2022
37
Fertility and Pregnancy Outcomes in Patients With Adenomyosis: Is Adenomyosis Synonymous With Infertility? 62
36381691 2022
38
Transient non-cyclical activity of external myometrium should be considered to avoid errors in diagnosis of adenomyosis and uterine anomalies. 62
34985801 2022
39
[Proliferative lesions with mesonephric features in the gynecologic tract: a clinicopathological analysis of sixteen cases]. 62
36207913 2022
40
Uterine disorders and iron deficiency anemia. 62
36182260 2022
41
Iron deficiency anemia: Impact on women's reproductive health. 62
36182259 2022
42
Chronic Pelvic Pain: A Comprehensive Review. 62
36465795 2022
43
The Role of Abnormal Uterine Junction Zone in the Occurrence and Development of Adenomyosis. 62
34515984 2022
44
Pituitary suppression with GnRH agonists before ART may be insufficient to treat women with severe adenomyosis. 62
36402667 2022
45
Adenomyosis-Associated Ischemic Stroke: Pathophysiology, Detection and Management. 62
36291343 2022
46
Decreased expression of GRIM-19 induces autophagy through the AMPK/ULK1 signaling pathway during adenomyosis†. 62
35908189 2022
47
Establishment of a novel mouse model of adenomyosis suitable for longitudinal and quantitative analysis and perinatal outcome studies. 62
36266437 2022
48
Applying contrast-enhanced ultrasound model to distinguish atypical focal adenomyosis from uterine leiomyomas. 62
36388773 2022
49
A case of didelphys uterus: tackling the double trouble adenomyosis and infertility. 62
35953315 2022
50
Nonsurgical management of adenomyosis: an overview of current evidence. 62
35895912 2022

Variations for Adenomyosis

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 BCL2 CTNNB1 ESR1 ITGB3 NGF PTEN
2
Show member pathways
13.7 VEGFA TP53 PTGS2 NGF MMP9 MMP2
3 13.55 BCL2 CTNNB1 ESR1 GPER1 ITGB3 MMP2
4
Show member pathways
13.41 VEGFA SPP1 PTEN MMP9 MMP2 ITGB3
5
Show member pathways
13.32 VEGFA TP53 PTGS2 MMP9 MMP2 BCL2
6
Show member pathways
12.95 VEGFA TP53 SPP1 PTEN NGF ITGB3
7 12.82 VEGFA SPP1 NGF MMP9 ITGB3 ESR1
8
Show member pathways
12.71 VEGFA TP53 PTGS2 PTEN CTNNB1 BCL2
9
Show member pathways
12.46 VEGFA MMP9 MMP2 CTNNB1
10
Show member pathways
12.45 TP53 PTEN ESR1 CTNNB1
11
Show member pathways
12.42 VEGFA PTGS2 ITGB3 ESR1 CTNNB1
12
Show member pathways
12.41 MMP9 MMP2 ESR1 BCL2
13 12.23 VEGFA SPP1 PTEN ITGB3 CTNNB1 BCL2
14
Show member pathways
12.23 TP53 PTGS2 PTEN NGF ESR1 CTNNB1
15
Show member pathways
12.21 TP53 PTEN ITGB3 BCL2
16 12.19 CTNNB1 MMP2 MMP9 TP53
17 12.1 VEGFA TP53 PTGS2 MMP9 MMP2 CTNNB1
18 12.07 VEGFA PTEN ITGB3 ESR1 BCL2
19 12.05 MMP9 MMP2 ITGB3 CTNNB1
20 12.04 TP53 SPP1 PTEN MMP2 BCL2
21 12 VEGFA PTGS2 CTNNB1 ANXA2
22 11.96 TP53 PTEN CTNNB1 BCL2
23 11.91 TP53 PTGS2 PTEN BCL2
24 11.89 VEGFA TP53 PTEN NGF MMP9 MMP2
25 11.87 ITGB3 MMP2 MMP9 PTGS2
26 11.86 ANXA2 GPER1 MMP2 PTEN VEGFA
27 11.81 TP53 ITGB3 CTNNB1
28 11.77 VEGFA TP53 PTEN CTNNB1
29 11.75 TP53 PTEN ESR1
30 11.74 CTNNB1 MMP2 MMP9
31 11.72 VEGFA TP53 MMP2 CTNNB1 BCL2
32 11.71 VEGFA TP53 MMP9 MMP2 BCL2
33 11.68 VEGFA ITGB3 CTNNB1
34 11.68 SPP1 MMP9 MMP2
35
Show member pathways
11.68 VEGFA PTGS2 MMP9 MMP2
36 11.68 VEGFA TP53 PTEN ESR1 CYP19A1 CTNNB1
37 11.67 VEGFA TP53 PTGS2 MMP9 MMP2 BCL2
38 11.63 VEGFA SPP1 ITGB3
39 11.63 MMP2 ESR1 BCL2
40 11.63 CTNNB1 MMP9 PTGS2 VEGFA
41 11.61 VEGFA TP53 PTGS2
42 11.6 TP53 PTEN MMP9 ESR1 CTNNB1
43 11.59 VEGFA MMP9 MMP2
44 11.56 TP53 PTEN CTNNB1
45 11.44 TP53 PTEN ESR1
46 11.44 VEGFA SPP1 ITGB3
47 11.43 VEGFA TP53 MMP9 MMP2
48 11.42 TP53 PTEN BCL2
49 11.38 VEGFA TP53 PTGS2 IGFBP1
50 11.36 TP53 PTGS2 ESR1

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath adaxonal region GO:0035749 8.92 PTEN ANXA2

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.43 VEGFA TP53 NGF ITGB3 GPER1 CTNNB1
2 negative regulation of gene expression GO:0010629 10.3 VEGFA TP53 GPER1 ESR1 CTNNB1
3 negative regulation of apoptotic process GO:0043066 10.29 VEGFA TP53 PTGS2 PTEN MMP9 CTNNB1
4 angiogenesis GO:0001525 10.27 VEGFA PTGS2 PTEN MMP2 ANXA2
5 negative regulation of cell population proliferation GO:0008285 10.25 TP53 PTGS2 PTEN NGF GPER1 CTNNB1
6 cell migration GO:0016477 10.24 PTEN MMP9 MMP2 ITGB3 BCL2
7 heart development GO:0007507 10.17 CTNNB1 MMP2 OXTR PTEN TP53
8 response to xenobiotic stimulus GO:0009410 10.14 TP53 PTGS2 OXTR MMP2 CTNNB1 BCL2
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.13 BCL2 NGF PTGS2 VEGFA
10 ovarian follicle development GO:0001541 10.11 BCL2 MMP2 VEGFA
11 reactive oxygen species metabolic process GO:0072593 10.1 TP53 NDUFA13 BCL2
12 cellular response to estradiol stimulus GO:0071392 10.1 MMP2 GPER1 ESR1
13 T cell differentiation in thymus GO:0033077 10.09 TP53 CTNNB1 BCL2
14 cellular response to hypoxia GO:0071456 10.07 BCL2 PTEN PTGS2 TP53 VEGFA
15 negative regulation of intrinsic apoptotic signaling pathway GO:2001243 10.02 NDUFA13 MMP9 BCL2
16 positive regulation of release of cytochrome c from mitochondria GO:0090200 10.01 TP53 MMP9 GPER1
17 response to oxidative stress GO:0006979 9.98 TP53 PTGS2 MMP2 BCL2
18 response to organic cyclic compound GO:0014070 9.96 PTGS2 OXTR IGFBP1 BCL2
19 uterus development GO:0060065 9.93 CYP19A1 ESR1 HOXA10
20 B cell lineage commitment GO:0002326 9.91 BCL2 TP53
21 androgen catabolic process GO:0006710 9.91 CYP19A1 SPP1
22 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.9 ESR1 TP53
23 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.89 TP53 VEGFA
24 response to estradiol GO:0032355 9.85 CTNNB1 CYP19A1 ESR1 OXTR PTGS2
25 T cell lineage commitment GO:0002360 9.81 TP53 BCL2
26 response to steroid hormone GO:0048545 9.81 SPP1 OXTR BCL2
27 positive regulation of estradiol secretion GO:2000866 9.8 SPP1 CYP19A1
28 response to cytokine GO:0034097 9.8 PTGS2 OXTR MMP2 BCL2
29 positive regulation of apoptotic process GO:0043065 9.8 TP53 PTGS2 MMP9 MMP2 GPER1 CTNNB1
30 response to radiation GO:0009314 9.73 PTGS2 MMP2 ITGB3 BCL2
31 embryo implantation GO:0007566 9.32 SPP1 PTGS2 MMP9 MMP2 ITGB3

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.92 TP53 ITGB3 BCL2 ANXA2
2 extracellular matrix binding GO:0050840 9.73 VEGFA SPP1 ITGB3
3 enzyme binding GO:0019899 9.73 TP53 PTGS2 PTEN ITGB3 ESR1 CTNNB1
4 fibronectin binding GO:0001968 9.63 VEGFA MMP2 ITGB3
5 nuclear estrogen receptor activity GO:0030284 8.92 GPER1 ESR1

Sources for Adenomyosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....